Cancer BiologyCell ReportsPeer-reviewed
Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within Interleukin-6 family cytokines
Anne Huber, Amr H. Allam, Christine Dijkstra…·Moritz F. Eissmann
This study identifies IL6/STAT3 signaling as a therapeutic target for TP53-mutant gastric cancer by showing its role in metastatic progression driven by mutant Trp53.
20 citations